27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- According to an SEC filing, Novavax Inc (NASDAQ: NVAX) has received an additional $147.3M as part of Operation Warp Speed to develop a COVID-19 vaccine dubbed NVX-CoV2373.
- This addition brings its total from the program to $1.74 billion, which was announced in July last year.
- President Joe Biden directly mentioned the company earlier this week, saying that upcoming vaccines, including one from Novavax, could be shared with other countries.
- Early data out this year showed its vaccine could keep up in efficacy terms with the vaccine leaders, namely Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX), and Moderna Inc (NASDAQ: MRNA).
- While behind in authorizations compared to its rivals, which also now include AstraZeneca Plc (NASDAQ: AZN) and Johnson & Johnson (NYSE: JNJ) (though both have been hit recently with some safety concerns), with the rise of variants and outbreaks in highly populated places like Brazil and India, it still has a place globally to deliver billions of doses.
- Price Action: NVAX shares are up 1.09% at $240.13 during the market session on the last check Friday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!